Please assess the completion status of the following clinical trial:

Trial Title: Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes for at least 6 months before trial start~* Treatment with at least 1000 mg metformin per day for at least 3 months~* Insulin-naive (short-term insulin treatment of up to 14 days is allowed)~* DPP-4 (dipeptidyl peptidase-4) inhibitor naive~* HbA1c (glycosylated haemoglobin A1c) between 7.5-10.0% by central laboratory analysis~* BMI (Body Mass Index) lesser than or equal to 45.0 kg/m2~* Able and willing to take one subcutaneous injection every day~* Able and willing to perform mandatory SMPG (self measured plasma glucose) measurements~Exclusion Criteria:~* Known or suspected allergy or intolerance to any of the trial products or related products~* Severe hypertension~* Treatment with thiazolidinedione (TZD) or GLP-1 (glucagon-like peptide-1) analogues within 2 months prior to trial start~* Cardiac disease, within the last 12 months~* Impaired hepatic function~* Impaired renal function~* Proliferative retinopathy or macular oedema requiring acute treatment~* Female of childbearing potential~* Known or suspected abuse of alcohol, narcotics or illicit substances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comb (Type: EXPERIMENTAL): Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
- Sita (Type: ACTIVE_COMPARATOR): Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).